Phase 2/3 trial of maintenance lapatinib after first-line chemotherapy in HER1/2-positive metastatic bladder cancer | Prof Thomas Powles at Annual Meeting 2015 - 101271

Spotlight
Video

Phase 2/3 trial of maintenance lapatinib after first-line chemotherapy in HER1/2-positive metastatic bladder cancer | Prof Thomas Powles at Annual Meeting 2015

EMJ has 458 videos Subscribe Here

Loading........
Description: At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles. MBBS, MRCP, MD, of Barts Cancer Institute, Queen Mary University of London, London, UK, discusses the results of a phase 2/3 trial, which evaluated if maintenance therapy with lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, after first-line chemotherapy is associated with clinical benefit in patients with HER1/2-positive metastatic transitional cell carcinoma.

–––

European Medical Journal

Website: http://emjreviews.com/...
Twitter: https://twitter.com/EMJRevi...
Facebook: https://www.facebook.com/em...
Shared By : EMJ
Posted on : 07/20/15
Added : 3 years ago
Category : Bladder Cancer



Recommended

Nothing found.

More From EMJ

Nothing found.